Medicinal Chemistry, Small Molecule Research, Pharma Research & Early Development (pRED), F. Hoffmann-La Roche AG, Grenzacherstrasse 124, 4070 Basel (Switzerland).
Angew Chem Int Ed Engl. 2014 Feb 3;53(6):1704-8. doi: 10.1002/anie.201309301. Epub 2014 Jan 23.
Drug discovery is a multifaceted endeavor encompassing as its core element the generation of structure-activity relationship (SAR) data by repeated chemical synthesis and biological testing of tailored molecules. Herein, we report on the development of a flow-based biochemical assay and its seamless integration into a fully automated system comprising flow chemical synthesis, purification and in-line quantification of compound concentration. This novel synthesis-screening platform enables to obtain SAR data on b-secretase (BACE1) inhibitors at an unprecedented cycle time of only 1 h instead of several days. Full integration and automation of industrial processes have always led to productivity gains and cost reductions, and this work demonstrates how applying these concepts to SAR generation may lead to a more efficient drug discovery process.
药物发现是一项多方面的努力,其核心要素包括通过反复的化学合成和针对特定分子的生物测试来生成结构-活性关系(SAR)数据。在这里,我们报告了一种基于流动的生化测定法的开发及其与一个完全自动化系统的无缝集成,该系统包括流动化学合成、纯化和化合物浓度的在线定量。这种新颖的合成-筛选平台能够在前所未有的 1 小时循环时间内获得β-分泌酶(BACE1)抑制剂的 SAR 数据,而不是几天。工业过程的全面集成和自动化始终会带来生产力的提高和成本的降低,这项工作表明,将这些概念应用于 SAR 的生成如何能够促进更有效的药物发现过程。